{
    "ticker": "RXI",
    "name": "RXI Pharmaceuticals Corporation",
    "description": "RXI Pharmaceuticals Corporation is a biotechnology company focused on developing innovative therapeutics based on its proprietary RNAi (RNA interference) technology. Founded in 2012 and headquartered in Worcester, Massachusetts, RXI aims to address significant unmet medical needs through the use of its unique platform for the targeted delivery of RNAi compounds. The company's lead product candidate, RXI-109, is designed to reduce scarring and improve wound healing, demonstrating significant potential in dermatological and ocular applications. RXI is also exploring various other therapeutic areas, including cardiovascular and autoimmune diseases, leveraging its expertise in RNAi to create effective and safe therapies. The company's commitment to scientific advancement is underscored by a robust pipeline and collaborations with leading research institutions. RXI Pharmaceuticals is at the forefront of a new era in medicine, aiming to develop solutions that can transform patient care and improve health outcomes through the power of RNA modulation.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "Worcester, Massachusetts, USA",
    "founded": "2012",
    "website": "http://www.rxipharma.com",
    "ceo": "Georgina W. H. Hall",
    "social_media": {
        "twitter": "https://twitter.com/RXIPharma",
        "linkedin": "https://www.linkedin.com/company/rxi-pharmaceuticals-corporation/"
    },
    "investor_relations": "http://www.rxipharma.com/investors",
    "key_executives": [
        {
            "name": "Georgina W. H. Hall",
            "position": "CEO"
        },
        {
            "name": "Dr. Robert L. B. Dorr",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Product Candidates",
            "products": [
                "RXI-109"
            ]
        }
    ],
    "seo": {
        "meta_title": "RXI Pharmaceuticals Corporation | RNAi Therapeutics and Innovations",
        "meta_description": "Explore RXI Pharmaceuticals Corporation, a leader in RNAi technology and innovative therapeutics aimed at addressing unmet medical needs.",
        "keywords": [
            "RXI Pharmaceuticals",
            "RNAi",
            "Biotechnology",
            "Pharmaceuticals",
            "RXI-109",
            "Innovative Therapies"
        ]
    },
    "faq": [
        {
            "question": "What is RXI Pharmaceuticals known for?",
            "answer": "RXI Pharmaceuticals is known for its development of innovative RNAi-based therapeutics."
        },
        {
            "question": "Who is the CEO of RXI Pharmaceuticals?",
            "answer": "Georgina W. H. Hall is the CEO of RXI Pharmaceuticals Corporation."
        },
        {
            "question": "Where is RXI Pharmaceuticals headquartered?",
            "answer": "RXI Pharmaceuticals is headquartered in Worcester, Massachusetts, USA."
        },
        {
            "question": "What is RXI-109?",
            "answer": "RXI-109 is RXI Pharmaceuticals' lead product candidate aimed at reducing scarring."
        },
        {
            "question": "When was RXI Pharmaceuticals founded?",
            "answer": "RXI Pharmaceuticals was founded in 2012."
        }
    ],
    "competitors": [
        "ALNY",
        "SGMO",
        "PGEN"
    ],
    "related_stocks": [
        "AMGN",
        "GILD",
        "BMY",
        "VRTX"
    ]
}